Key Documents

Curriculum Vitae available Online

Terence Ketter

Professor, Psychiatry & Behavioral Science - Psychopharmacology

Contact Information

Clinical Offices

Psychiatry Department 401 Quarry Rd MC 5723 Stanford, CA 94305-5723
Telephone Work (650) 723-8335 Fax (650) 723-2507
Academic Offices

Personal Information
Email tketter@stanford.edu Tel (650) 723-2515
Not for medical emergencies or patient use

Clinical Focus

Psychiatry

Administrative Appointments

Chief, Bipolar Disorders Clinic , (1995– 2004 )

Honors and Awards

Distinguished Fellow, American Psychiatric Association (2006)
Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (2003-2005)
Outstanding Faculty Physician Award, Vaden Health Center, Stanford University (2002)
Independent Investigator Award, National Alliance for Research in Schizophrenia and Depression (1999-2001)
Independent Investigator Award, Stanley Foundation Research Award Program (1996-2000)
Mead Johnson Travel Award Fellow, American College of Neuropsychopharmacology (1994)
Creative Resident Award, University of California, San Francisco (1988)
Walter F. Watkins Scholarship, University of Toronto School of Medicine (1982)
Governor General's Silver Medal, Erindale College, University of Toronto (1973)

Professional Education

National Institute of Health (1995) MD
Board Certification: Psychiatry, American Board of Psychiatry and Neurology (1989)
UCSF Medical Center (1988) CA
UCSF Medical Center (1985) CA
University of Toronto (1984) Canada
BSc, University of Toronto Mathematics (1973)
MSc, Sydney University Mathematics (1976)

Postdoctoral Advisees

Shefali Srivastava

Graduate & Fellowship Program Affiliations

Web Site Links

Stanford Bipolar DIosrders Clinic

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.

Consulting: AstraZenica, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer

Research Interests

Dr. Ketter has done extensive research into the etiology, phenomenology, and treatment of bipolar disorder. His etiologic research has focused on the use of brain imaging methods such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) to better understand the neurobiology of mood disorders and to explore the possibility of using these techniques to more effectively target treatments for patients with bipolar disorder. His phenomenologic research has focused on the development and course of bipolar disorder in late adolescence and young adulthood, particularly in college students, and links between creativity, temperament, and mood disorders. His research into treatment has involved clinical trials of novel medications and combinations of medications in the treatment of bipolar disorder, with an emphasis on the use of anticonvulsants.

Clinical Trials

Short Term Rescue Study of Olanzapine Recruiting

Publications

Insulin resistance and hyperlipidemia in women with bipolar disorder. Stemmle PG, Kenna HA, Wang PW, Hill SJ, Ketter TA, Rasgon NL. J Psychiatr Res. 2009; 43 (3): 341-3
Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission. Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ. J Psychiatr Res. 2009;
Decreased prefrontal, anterior cingulate, insula, and ventral striatal metabolism in medication-free depressed outpatients with bipolar disorder. Brooks JO, Wang PW, Bonner JC, Rosen AC, Hoblyn JC, Hill SJ, Ketter TA. J Psychiatr Res. 2009; 43 (3): 181-8
Treating bipolar disorder: monotherapy versus combination therapy. Ketter TA, J Clin Psychiatry. 2009; 70 (2): e42
Divalproex extended-release in acute bipolar II depression. Wang PW, Nowakowska C, Chandler RA, Hill SJ, Nam JY, Culver JL, Keller KL, Ketter TA. J Affect Disord. 2009;
Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression. Brooks JO, Bonner JC, Rosen AC, Wang PW, Hoblyn JC, Hill SJ, Ketter TA. Psychiatry Res. 2009; 172 (3): 200-4
Incorporating trial data into bipolar disorder management. Ketter TA, J Clin Psychiatry. 2008; 69 (7): e21
Combination therapy versus monotherapy in bipolar disorder. Ketter TA, J Clin Psychiatry. 2008; 69 (12): e34
Increased frequency of depressive episodes during the menopausal transition in women with bipolar disorder: preliminary report. Marsh WK, Templeton A, Ketter TA, Rasgon NL. J Psychiatr Res. 2008; 42 (3): 247-51
A new US-UK diagnostic project: mood elevation and depression in first-year undergraduates at Oxford and Stanford universities. Chandler RA, Wang PW, Ketter TA, Goodwin GM. Acta Psychiatr Scand. 2008; 118 (1): 81-5
Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. Wang PW, Yang YS, Chandler RA, Nowakowska C, Alarcon AM, Culver J, Ketter TA. J Psychiatr Res. 2008; 42 (6): 451-7
Caregiver burden and health in bipolar disorder: a cluster analytic approach. Perlick DA, Rosenheck RA, Miklowitz DJ, Kaczynski R, Link B, Ketter T, Wisniewski S, Wolff N, Sachs G. J Nerv Ment Dis. 2008; 196 (6): 484-91
Effectiveness of lamotrigine in bipolar disorder in a clinical setting. Ketter TA, Brooks JO, Hoblyn JC, Champion LM, Nam JY, Culver JL, Marsh WK, Bonner JC. J Psychiatr Res. 2008; 43 (1): 13-23
Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Sommer BR, Fenn HH, Ketter TA. Expert Opin Drug Saf. 2007; 6 (2): 133-45
Introduction - advancing understanding of the effectiveness of quetiapine in acute mania. Ketter TA, J Affect Disord. 2007; 100 Suppl 1 S1-3
Effectiveness of adjunctive antidepressant treatment for bipolar depression. Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MJ, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB, Thase ME. N Engl J Med. 2007; 356 (17): 1711-22
Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Cookson J, Keck PE, Ketter TA, Macfadden W. Int Clin Psychopharmacol. 2007; 22 (2): 93-100
Bipolar disorder: improving diagnosis and optimizing integrated care. Culver JL, Arnow BA, Ketter TA. J Clin Psychol. 2007; 63 (1): 73-92
Enhanced creativity in bipolar disorder patients: a controlled study. Santosa CM, Strong CM, Nowakowska C, Wang PW, Rennicke CM, Ketter TA. J Affect Disord. 2007; 100 (1-3): 31-9
Temperament-creativity relationships in mood disorder patients, healthy controls and highly creative individuals. Strong CM, Nowakowska C, Santosa CM, Wang PW, Kraemer HC, Ketter TA. J Affect Disord. 2007; 100 (1-3): 41-8
Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania. Ketter TA, Jones M, Paulsson B. J Affect Disord. 2007; 100 Suppl 1 S45-53
Adjunctive aripiprazole in treatment-resistant bipolar depression. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM. Ann Clin Psychiatry. 2006 Jul-Sep; 18 (3): 169-72
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice. Ketter TA, Haupt DW. Curr Med Res Opin. 2006; 22 (12): 2345-53
Incidence and time course of subsyndromal symptoms in patients with bipolar I disorder: an evaluation of 2 placebo-controlled maintenance trials. Frye MA, Yatham LN, Calabrese JR, Bowden CL, Ketter TA, Suppes T, Adams BE, Thompson TR. J Clin Psychiatry. 2006; 67 (11): 1721-8
Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Ketter TA, Nasrallah HA, Fagiolini A. Psychopharmacol Bull. 2006; 39 (1): 120-46
The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. Ketter TA, Greist JH, Graham JA, Roberts JN, Thompson TR, Nanry KP. J Clin Psychiatry. 2006; 67 (3): 400-6
Overweight and obesity in bipolar disorders. Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, Sagduyu K, Miyahara S, Ketter TA. J Psychiatr Res. 2006; 40 (8): 762-4
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes. Ketter TA, Houston JP, Adams DH, Risser RC, Meyers AL, Williamson DJ, Tohen M. J Clin Psychiatry. 2006; 67 (1): 95-101
Preliminary evidence of differential relations between prefrontal cortex metabolism and sustained attention in depressed adults with bipolar disorder and healthy controls. Brooks JO, Wang PW, Strong C, Sachs N, Hoblyn JC, Fenn R, Ketter TA. Bipolar Disord. 2006; 8 (3): 248-54
Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash. Ketter TA, Wang PW, Chandler RA, Alarcon AM, Becker OV, Nowakowska C, O'Keeffe CM, Schumacher MR. J Clin Psychiatry. 2005; 66 (5): 642-5
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Keck PE, Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M. J Clin Psychiatry. 2005; 66 (5): 611-6
Temperamental commonalities and differences in euthymic mood disorder patients, creative controls, and healthy controls. Nowakowska C, Strong CM, Santosa CM, Wang PW, Ketter TA. J Affect Disord. 2005; 85 (1-2): 207-15
The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC. J Clin Psychiatry. 2005; 66 (7): 870-86
Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Chang K, Barnea-Goraly N, Karchemskiy A, Simeonova DI, Barnes P, Ketter T, Reiss AL. Biol Psychiatry. 2005; 58 (3): 197-203
Creativity in familial bipolar disorder. Simeonova DI, Chang KD, Strong C, Ketter TA. J Psychiatr Res. 2005; 39 (6): 623-31
Clinical use of carbamazepine for bipolar disorders. Wang PW, Ketter TA. Expert Opin Pharmacother. 2005; 6 (16): 2887-902
Psychosocial service utilization by patients with bipolar disorders: data from the first 500 participants in the Systematic Treatment Enhancement Program. Lembke A, Miklowitz DJ, Otto MW, Zhang H, Wisniewski SR, Sachs GS, Thase ME, Ketter TA. J Psychiatr Pract. 2004; 10 (2): 81-7
Lamotrigine therapy in treatment-resistant menstrually-related rapid cycling bipolar disorder: a case report. Becker OV, Rasgon NL, Marsh WK, Glenn T, Ketter TA. Bipolar Disord. 2004; 6 (5): 435-9
Psychotic bipolar disorders: dimensionally similar to or categorically different from schizophrenia? Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang Y. J Psychiatr Res. 2004; 38 (1): 47-61
New medication treatment options for bipolar disorders. Ketter TA, Wang PW, Nowakowska C, Marsh WK. Acta Psychiatr Scand Suppl. 2004; (422): 18-33
A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. Ketter TA, Kalali AH, Weisler RH. J Clin Psychiatry. 2004; 65 (5): 668-73
Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. Chang KD, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. J Clin Psychiatry. 2003; 64 (8): 936-42
Decreased N-acetylaspartate in children with familial bipolar disorder. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. Biol Psychiatry. 2003; 53 (11): 1059-65
Bipolar offspring: a window into bipolar disorder evolution. Chang K, Steiner H, Dienes K, Adleman N, Ketter T. Biol Psychiatry. 2003; 53 (11): 945-51
The diverse roles of anticonvulsants in bipolar disorders. Ketter TA, Wang PW, Becker OV, Nowakowska C, Yang YS. Ann Clin Psychiatry. 2003; 15 (2): 95-108
Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. Ketter TA, Manji HK, Post RM. J Clin Psychopharmacol. 2003; 23 (5): 484-95
Temperament characteristics of child and adolescent bipolar offspring. Chang KD, Blasey CM, Ketter TA, Steiner H. J Affect Disord. 2003; 77 (1): 11-9
The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. Ketter TA, Wang PW. J Clin Psychiatry. 2003; 64 Suppl 3 15-20
New anticonvulsant medication uses in bipolar disorder. Wang PW, Ketter TA, Becker OV, Nowakowska C. CNS Spectr. 2003; 8 (12): 930-2, 941-7
Studies of offspring of parents with bipolar disorder. Chang K, Steiner H, Ketter T. Am J Med Genet C Semin Med Genet. 2003; 123C (1): 26-35
Gabapentin augmentation therapy in bipolar depression. Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA. Bipolar Disord. 2002; 4 (5): 296-301
Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders. Janenawasin S, Wang PW, Lembke A, Schumacher M, Das B, Santosa CM, Mongkolcheep J, Ketter TA. Bipolar Disord. 2002; 4 (5): 328-34
Pharmacokinetics of mood stabilizers and new anticonvulsants. Wang PW, Ketter TA. Psychopharmacol Bull. 2002; 36 (1): 44-66
Impaired recognition of facial emotion in mania. Lembke A, Ketter TA. Am J Psychiatry. 2002; 159 (2): 302-4
Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. Ketter TA, Calabrese JR. J Clin Psychiatry. 2002; 63 (2): 146-51
Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. Ketter TA, Wang PW. J Clin Psychiatry. 2002; 63 Suppl 3 21-5
Special issues in the treatment of paediatric bipolar disorder. Chang KD, Ketter TA. Expert Opin Pharmacother. 2001; 2 (4): 613-22
Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. J Affect Disord. 2001; 67 (1-3): 207-12
Family environment of children and adolescents with bipolar parents. Chang KD, Blasey C, Ketter TA, Steiner H. Bipolar Disord. 2001; 3 (2): 73-8
Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM. Biol Psychiatry. 2001; 49 (2): 97-109
Psychiatric phenomenology of child and adolescent bipolar offspring. Chang KD, Steiner H, Ketter TA. J Am Acad Child Adolesc Psychiatry. 2000; 39 (4): 453-60
Biology and recent brain imaging studies in affective psychoses. Wang PW, Ketter TA. Curr Psychiatry Rep. 2000; 2 (4): 298-304
Mood stabilizer augmentation with olanzapine in acutely manic children. Chang KD, Ketter TA. J Child Adolesc Psychopharmacol. 2000; 10 (1): 45-9
Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA. Biol Psychiatry. 2000; 47 (6): 475-81
Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Ketter TA, Kimbrell TA, George MS, Willis MW, Benson BE, Danielson A, Frye MA, Herscovitch P, Post RM. Biol Psychiatry. 1999; 46 (10): 1364-74
Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Ketter TA, Post RM, Theodore WH. Neurology. 1999; 53 (5 Suppl 2): S53-67
Metabolism and excretion of mood stabilizers and new anticonvulsants. Ketter TA, Frye MA, Corá-Locatelli G, Kimbrell TA, Post RM. Cell Mol Neurobiol. 1999; 19 (4): 511-32
Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Marangell LB, Ketter TA, George MS, Pazzaglia PJ, Callahan AM, Parekh P, Andreason PJ, Horwitz B, Herscovitch P, Post RM. Am J Psychiatry. 1997; 154 (2): 224-30
Anterior paralimbic mediation of procaine-induced emotional and psychosensory experiences. Ketter TA, Andreason PJ, George MS, Lee C, Gill DS, Parekh PI, Willis MW, Herscovitch P, Post RM. Arch Gen Psychiatry. 1996; 53 (1): 59-69
Functional brain imaging, limbic function, and affective disorders. Ketter TA, George MS, Kimbrell TA, Benson BE, Post RM. The Neuroscientist. 1996; 1 (2): 55-65